SUMMARY
Chronic thromboembolic pulmonary hypertension (CTEPH) caused by incomplete resolution of thromboemboli and irreversible remodelling of the pulmonary arteries is a progressive and without treatment a fatal disease. The exact prevalence and incidence of disease are unknown, probably are underestimated. Splenectomy, infected ventriculoatrial shunts, thyroid replacement therapy, malignancy and chronic inflammatory diseases, including osteomyelitis and inflammatory bowel disease, are conditions clearly associated with CTEPH and thus represent negative prognostic factors. In recent years it has been succeeded to significantly reduce high morbidity and mortality thanks to availability of specific treatment for the disease.

These include surgical and interventional treatment (potentially curable pulmonary endarterectomy and balloon pulmonary angioplasty) and for unsuitable candidates specific pharmacotherapy. The individual risk of developing of CTEPH after splenectomy is currently unknown. The cause of this complication after splenectomy is probably multifactorial, not completely investigated. Further research is needed to identify markers of coagulation chain factors that would predict the development of CTEPH in this patient population.
Key words: chronic thromboembolic poulmonary hypertension, splenectomy .
Lek Obz, 2022, 71 (2): 70-75

Drahomíra BOLLOVÁ 1, Iveta ŠIMKOVÁ 2

1 Interné oddelenie s JIS NsP Galanta a LF SZU, Bratislava, primár oddelenia MUDr. R. Klučka
2 Klinika kardiológie a angiológie LF SZU a NÚSCH, a.s., Bratislava, vedúca lekárka Expertízneho pracoviska pre CTEPH, prof. MUDr. I. Šimková, CSc.

CITE:
BOLLOVÁ D., ŠIMKOVÁ I.: Chronic thromboembolic pulmonary hypertension development after splenectomy - current opinion. Lek Obz, 2022, 71 (2): 70-75